New cancer drug targets two proteins at once in early trial

NCT ID NCT07181681

Recruiting now Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them. The study will first find a safe dose and then look for signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BG-C0902 (an antibody-drug conjugate that targets EGFR and MET proteins on cancer cells and delivers a chemotherapy-like payload)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial with only 63 participants, so the drug may not be safe or effective. Side effects from the chemotherapy-like payload are possible, and the drug may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Blacktown Cancer and Haematology Centre
RECRUITING

Blacktown, New South Wales, NSW 2148, Australia
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Cancer Research South Australia
RECRUITING

Adelaide, South Australia, SA 5000, Australia
Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Monash Health
RECRUITING

Clayton, Victoria, VIC 3168, Australia
Next Oncology
RECRUITING

San Antonio, Texas, 78229-6028, United States
Next Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Rui Jin Hospital Shanghai Jiao Tong University School of Medicinejiading Branch
RECRUITING

Shanghai, Shanghai Municipality, 201801, China
The Alfred Hospital
RECRUITING

Melbourne, Victoria, VIC 3004, Australia
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361003, China
The University of Texas Md Anderson Cancer Center
RECRUITING

Houston, Texas, 77030-4009, United States
West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.